Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 1/20 | 0.68 |
| ▸ | SLC40A1 | Q9NP59 | 10/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.67 |
| ▸ | NFKBIA | P25963 | 3/20 | 0.67 |
| ▸ | RELA | Q04206 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | AKT1 | P31749 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | MDM4 | O15151 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.58 |
| ▸ | G6PD | P11413 | 1/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507919 | 0.87 | SLC40A1 (0.76) | GAASLC40A1MEN1KMT2ATDP1 | |
| SCHEMBL30854809 | 0.87 | SLC40A1 (0.76) | GAASLC40A1MEN1KMT2ATDP1 | |
| SCHEMBL14919826 | 0.86 | GAA (0.71) | GAASLC40A1MEN1KMT2ATDP1 | |
| SCHEMBL7896798 | 0.86 | SLC40A1 (0.80) | GAASLC40A1MEN1KMT2ATDP1 | |
| SCHEMBL22234047 | 0.83 | GAA (0.71) | GAASLC40A1MEN1KMT2ATDP1 | |
| SCHEMBL29540765 | 0.83 | GAA (0.71) | GAASLC40A1MEN1KMT2ATDP1 | |
| SCHEMBL50688 | 0.82 | MAPK1 (1.00) | GAACA1CA2MAPK1CA9 | |
| SCHEMBL29470241 | 0.82 | MAPK1 (1.00) | GAACA1CA2MAPK1CA9 | |
| SCHEMBL7388562 | 0.82 | MEN1 (0.70) | GAASLC40A1MEN1KMT2ATDP1 | |
| SCHEMBL460773 | 0.81 | SLC40A1 (1.00) | GAASLC40A1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101945859-B | Bis-(sulfonylamino) derivatives in therapy | ASTRAZENECA AB | 2014-04-09 | — | — | CN | claimed |
| EP-2234993-B1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2012-11-07 | — | — | EP | claimed |
| CN-101945859-A | Bis-(sulfonylamino) derivatives in therapy | ASTRAZENECA AB | 2011-01-12 | — | — | CN | claimed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | claimed |
| EP-2234993-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | claimed |
| WO-2009082347-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | claimed |
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | claimed |
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| EP-2234993-B1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2012-11-07 | — | — | EP | disclosed |
| CN-101945859-A | Bis-(sulfonylamino) derivatives in therapy | ASTRAZENECA AB | 2011-01-12 | — | — | CN | disclosed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| EP-2234993-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009082347-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | PTGER1, SULT2A1, SULT1E1 | GAA 1317/4885CA1 3346/4885CA2 2435/4885 |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | PTGER1, SULT2A1, SULT1E1 | GAA 1597/4885CA1 3319/4885CA2 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.